Novavax Logo

GAITHERSBURG, Md., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the first volunteers have been enrolled in the Phase 2 portion of its ongoing clinical trial to evaluate the immunogenicity and safety of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The Phase 2 clinical trial expands on the age range of the Phase 1 portion by including older adults 60-84 years of age as approximately 50 percent of the trial’s population. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.



Women Building Bio is where the vision is transformed into reality. Women advancing the industry with all stakeholders, men and women, front and center joining forces.

Come join us for this half day interactive virtual conference on September 16, 2020.

Click here to register.

emergent biosolutions

GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf life of NARCAN® (naloxone HCl) Nasal Spray from 24 months to 36 months. Narcan Nasal Spray was the first intranasal form of naloxone approved by FDA and Health Canada for the emergency treatment of known or suspected opioid overdose.


Alexandria Logo

PASADENA, Calif., Aug. 13, 2020 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT and the first, longest-tenured and pioneering owner, operator and developer uniquely focused on collaborative life science, technology and agtech campuses in AAA innovation cluster locations, is at the vanguard of the vital life science ecosystem that is advancing solutions for COVID-19 through a multifaceted, highly impactful strategy that includes a mission-critical focus on making rapid COVID-19 testing available to all Americans. Widespread screening and diagnostic testing, in addition to safe and effective vaccines and therapies, are desperately needed to resolve the global COVID-19 pandemic.


Shallow Focus Photography of Microscope Free Stock Photo

Our annual cluster ranking profiles the top U.S. life sciences hubs and tracks the progress of the up-andcoming life sciencesmarkets that are fast becoming options of choice for life sciences companies and investors alike. Finally, the outlook introduces prominent industry trends that will provide new engines of growth.

In this report

In addition to highlighting the current state of life sciences real estate clusters across the U.S., this report will provide answers to three critical questions that both life sciences companies and lab developers must consider in order to remain at the crest of industry trends.

Qiagen Logo

Venlo, The Netherlands, August 13, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will continue to execute its successful growth strategy aiming to create significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific, Inc. (NYSE: TMO) did not achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders.


Precigen Logo

GERMANTOWN, Md., Aug. 17, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with Precigen's PRGN-2009, a first-in-class, off-the-shelf (OTS) investigational immunotherapy utilizing the AdenoVerse™ platform designed to activate the immune system to recognize and target HPV+ solid tumors (clinical trial identifier: NCT04432597). HPV-associated cancers represent a significant health burden in indications such as head and neck, cervical, vaginal and anal cancer.


United Therapeutics Logo

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 17, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for Tyvaso® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics expects the agency's review to be complete in April 2021.


Emmes Logo

ROCKVILLE, Md., Aug. 12, 2020 /PRNewswire/ -- Emmes today announced that it provided the data and statistical analysis support for the Phase 1 clinical trial of the investigational COVID-19 vaccine mRNA-1273.  Three Emmes employees were co-authors on the Preliminary Report about the clinical trial, "An mRNA Vaccine against SARS-CoV-2," published in the New England Journal of Medicine on July 14.


TEDCO s Maryland Innovation Initiative Accelerates Technologies from Bench to Market TEDCO

COLUMBIA, Md. (August 13, 2020)— TEDCO, Maryland’s economic engine for technology companies, announced its recent round of investments in six (6) start-up companies and funding to  fifteen (15) university projects through the Maryland Innovation Initiative (MII). 

Established in 2012, the MII program was created as a partnership between the State of Maryland and five Maryland academic research institutions: Johns Hopkins University; Morgan State University; University of Maryland, Baltimore; University of Maryland, Baltimore County; and University of Maryland, College Park. The program’s mission is to accelerate promising technologies with significant commercial potential to market while leveraging each partner University’s strengths. 



We sourced the community, built a roster of Greater Washington’s hottest enterprises and innovators, and narrowed that list to the ecosystem’s 50 elite.

Then Thursday afternoon, we celebrated those fast-growing, move-making players: DC Inno’s 2020 Inno on Fire winners. All had banner years — for expansions, launches, fundraises and pivots — and all in a time of profound, unprecedented change.



The 2020 Technology Showcase is going virtual! Reserve the afternoon of September 9th on your calendar for the 2020 Technology Showcase. The 4th annual event will highlight technologies being developed at the NCI and the Frederick National Laboratory for Cancer Research (FNL) to encourage technology licensing and collaborations, startup company formation and the translation of NCI discoveries into solutions to benefit patients. 


Af0673c6 459c 4a23 bb6e 9ecc97acb5eb pdf

Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500® urban office REIT, is the first and longest-tenured owner, operator, and developer uniquely focused on collaborative life science, technology and agtech campuses in AAA innovation cluster locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in life science, technology, and agtech campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. For more information, please visit

Alex Philippidis

Originally Aired: August 12, 2020 Time: 3:00 pm ET

Gene therapy has undergone a renaissance in recent years, with several drugs offering beneficial, even life-saving treatments, now approved by the FDA and EMA. A big reason for this turnaround is the emergence of adeno-associated virus (AAV) as a generally safe and efficient vector for therapeutic gene delivery.

Earlier this summer, reports emerged of two fatalities in young boys in a clinical trial for a rare muscle disorder using AAV. This sad news has turned the spotlight on viral dosage, vector manufacturing and immune responses as factors we need to better understand to ensure the safety of gene therapy treatments in the future.



The incubation period of a disease is the time between infection and the emergence of symptoms. Although it varies from person to person, understanding the average incubation period of an infectious disease is critical to controlling it.

Authorities use the incubation period to determine the length of quarantine, for instance, as well as to understand how the disease is transmitted and to identify the source of the outbreak.



It takes no time for Francis Collins, the director of the National Institutes of Health, to recall the moment when he knew he wanted to be a scientist. “Tenth-grade chemistry class,” he says over the phone from his home office in Chevy Chase, Md., where he has been working since most of the NIH campus in Bethesda, Md., shut down in March. Much of the science he had learned before then was “descriptive” and uninteresting, he explains—but for this class, students used experiments to figure things out. “It became clear to me that science is like a detective story,” says Dr. Collins, 70. “If you’re good at it, you’ll discover...


This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses. A novel coronavirus, named Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China in 2019. The illness caused by this virus has been named coronavirus disease 2019 (COVID-19). (CDC/Alissa Eckert, MS)

Montgomery County is closing all testing sites Friday until further notice after issues were raised by the state with some testing kits.

Anyone who was tested at a county-sponsored clinic in the past two weeks should be retested at another community-based clinic, the county said on its website.

Maryland's department of health raised questions about protocols used with some test kits by AdvaGenix, which uses self-administered kits to collect saliva. These kits account for about 7% of all tests conducted in the county, adding up to hundreds every day. 


Bendis Alms Skyscraper 2

BioHealth Innovation (BHI) was created in 2012 by Rich Bendis and key industry leaders to accelerate the commercialization of high potential scientist entrepreneurs and companies within the BioHealth Capital Region (BHCR), which consists of Maryland, Virginia and Washington, D.C.

Prior to BHI’s launch, the region’s development efforts were heavily focused on academic and government research assets. BHI’s mission is to give the life science industry a greater voice within the region and to be more market and entrepreneur-driven. During the last 8.5 years, BHI has grown substantially and spearheaded the effort to create a strong regional brand that is now known as the BHCR.

Download the PDF

NCC PDI Pediatric Medical Device Pitch Competition Deadline Extended Children s National Hospital

Reporting to Vice President and Chief Innovation Officer, the senior licensing associate independently manages a docket of technologies and has advanced level skills in technology marketing and licensing. The individual assumes primary responsibility for directly facilitating the technology transfer, development and commercialization of assigned technologies and faculty/departmental clients, assisting faculty and staff with the establishment of new commercialization agreements and business development relationships, supporting the establishment of R&D collaborations with industry partners to advance early stage discoveries, and managing relationships with key stakeholders internal and external the organization to proactively enable technology transfer. The Senior Licensing Associate will provide high quality services including invention receipt and capture, patentability assessment, market outreach (in-depth marketing support strategic and tactical), business development (structuring, drafting and negotiating commercialization agreements) and shall deliver the highest quality of customer service. This position will also manage other functions for the office as assigned in addition to technology licensing. 


Lisa AND Rich

The BioHealth Capital Region and BioForward Wisconsin come together as Lisa Johnson joins Rich Bendis on BioTalk to discuss her career, the industry, and growing biohealth in the Midwest. 

Listen now via Google, Apple,, Spotify, TuneIn, and YouTube Audio

Novavax Logo

GAITHERSBURG, Md. and OSAKA, Japan, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year1.


Adaptive Phage Therapeutics Logo

GAITHERSBURG, Md.--(BUSINESS WIRE)--Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed $1.75M as a lead investor in a $7 million convertible note financing round.


Sm Business Resource List FNL 072820 pdf

Download an A to Z business guide that offers federal, state and local resources to help your Montgomery County business succeed. The newly expanded, 14-page MCEDC Business Resource Guide. Find funding, training, talent, support for women and diverse businesses and more—a handy guide to use and share.

Click here to download.

emergent logo

GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it intends to offer $400 million aggregate principal amount of senior unsecured notes with an expected maturity date of August 2028 (the “Notes”). The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by all of the Company’s direct and indirect subsidiaries that guarantee debt under its credit facilities. The Company intends to use the net proceeds of the offering to repay the $353 million outstanding under its $600 million revolving credit facility with the remainder to be used for general corporate purposes.


Emmes Promotes Three VPs to Officer Positions State heraldmailmedia com

ROCKVILLE, Md., Aug. 6, 2020 /PRNewswire/ -- Emmes today announced that three corporate vice presidents have been promoted. Dr. Traci Clemons has been named chief research officer, Marian Ewell is now chief scientific innovation officer, and Jennifer Hester is the company's chief human resources officer. These are all newly created positions for the company.

Image: Dr. Traci Clemons


GAITHERSBURG, Md., July 23, 2020 /PRNewswire/ -- Shreis Scalene Therapeutics LLC (SSTx), a MD-USA-based medical device company will fast-track the manufacture and distribution of the CE-marked (EU-Class 1) Scalene Hypercharge Corona Canon (SHYCOCAN) under US FDA 'Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency."

Image: SHYCOCAN Devices

Alexandria Logo

With so much attention on COVID-19 treatment and vaccine developments, life science laboratories are getting more notice.

Alexandria Real Estate Equities (NYSE:ARE) is a real estate investment trust (REIT) based in Pasadena, California. It’s the largest landlord in the US for laboratories and related offices.

Its top companies by rent revenues include Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY), Celgene, Eli Lilly (NYSE:LLY), Merck (NYSE:MRK)—which we own in Profitable Investing—Moderna (NASDAQ:MRNA), Novartis (NYSE:NVS), Pfizer (NYSE:PFE) and Sanofi (NASDAQ:SNY).


Roundcube Webmail BioTechEmailMailer card 2020 15JUL 2 pdf

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, Virginia Bio, Children’s National Health System, Johns Hopkins University, JPMorgan, Maryland Department of Commerce, George Mason University, University System of Maryland, Wilson Sonsini Goodrich & Rosati and AstraZeneca.

The BioHealth Capital Region—Maryland, Virginia, and Washington, DC—sets the bar high for biotech innovation. So please join us for our 6th Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

For more information about our speakers and event schedule, please visit



The University of Maryland School of Medicine and about 30 other U.S. centers have begun recruiting thousands of volunteers living in COVID-19 hot spots to join the nation’s most advanced trial for a vaccine against the disease.

The vaccine was developed by the Massachusetts biotech company Moderna along with the National Institutes of Health. It is among several vaccines to reach a Phase 3 trial globally but was the first one announced under Operation Warp Speed, the federal program to quickly identify, produce and distribute 300 million doses of a COVID-19 vaccine.


PHILADELPHIA, Aug. 5, 2020 /PRNewswire/ -- GSK today launched a national campaign to help increase low rates of vaccination among older adults. The campaign, Brought to You By Vaccines, will educate adults ages 50 and older about the value of vaccines and the urgent need to talk to their healthcare provider or pharmacist about the recommended vaccines they need or may have recently missed.


20/20 Gene Systems

ROCKVILLE, Md.--(BUSINESS WIRE)-- 20/20 GeneSystems, Inc. is proud to announce that in partnership with Linkou Chang Gung Memorial Hospital, the largest hospital in Taiwan, it has won the 2020 Taipei Biotech "Technology Transfer Cooperation Award" Gold Medal Award, the Oscar in the biotechnology industry, for its OneTest an artificial intelligence (AI) powered blood test that can assist in the early detection of many common cancers.